University of California San Francisco

Poor melanoma outcomes and survival in Asian American and Pacific Islander patients.

Zheng YJ, Ho C, Lazar A, Ortiz-Urda S PMID: 32860918

A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma.

Algazi AP, Rotow J, Posch C, Ortiz-Urda S, Pelayo A, Munster PN, Daud A PMID: 30801911

MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and 'wild type' melanomas.

Posch C, Sanlorenzo M, Ma J, Kim ST, Zekhtser M, Ortiz-Urda S PMID: 30405888

The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma.

Sanlorenzo M, Vujic I, Esteve-Puig R, Lai K, Vujic M, Lin K, Posch C, Dimon M, Moy A, Zekhtser M, Johnston K, Gho D, Ho W, Gajjala A, Oses Prieto J, Burlingame A, Daud A, Rappersberger K, Ortiz-Urda S PMID: 30026510

Cutaneous CD56+ T-cell lymphoma developing during pembrolizumab treatment for metastatic melanoma.

Zheng YJ, Lee A, Pincus L, Ho W, Vujic M, Ortiz-Urda S PMID: 29892669

Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.

Algazi AP, Esteve-Puig R, Nosrati A, Hinds B, Hobbs-Muthukumar A, Nandoskar P, Ortiz-Urda S, Chapman PB, Daud A PMID: 28921907

New insights in melanoma biomarkers: long-noncoding RNAs.

Moreno-Traspas R, Vujic I, Sanlorenzo M, Ortiz-Urda S PMID: 30190889

Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo.

Posch C, Moslehi H, Sanlorenzo M, Green G, Vujic I, Panzer-Grümayer R, Rappersberger K, Ortiz-Urda S PMID: 27322141

Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells.

Posch C, Sanlorenzo M, Vujic I, Oses-Prieto JA, Cholewa BD, Kim ST, Ma J, Lai K, Zekhtser M, Esteve-Puig R, Green G, Chand S, Burlingame AL, Panzer-Grümayer R, Rappersberger K, Ortiz-Urda S PMID: 27251789

Oncogenic KIT mutations in different exons lead to specific changes in melanocyte phospho-proteome.

Sanlorenzo M, Vujic I, Posch C, Ma J, Lin K, Lai K, Lee D, Vujic M, Oses-Prieto JA, Chand S, Rodriguez-Peralto JL, Burlingame A, Ortiz-Urda S PMID: 27216642